首页> 美国卫生研究院文献>other >Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention
【2h】

Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention

机译:经皮冠状动脉介入治疗后支架内再狭窄患者血栓素样氧化型低密度脂蛋白受体-1的临床分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In-stent restenosis (ISR) is the most common complication associated with percutaneous coronary intervention (PCI). Although some studies have reported an association between lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and ISR, not enough clinical validation data are available to support this link. Here, we report our cross-sectional study aimed at exploring the feasibility of LOX-1 as a biomarker for the prognostic diagnosis of patients undergoing PCI.Three groups were included: ISR group, including 99 patients with ISR diagnosed with coronary arteriography (CAG) after PCI; lesion group, comprising 87 patients with coronary artery stenosis (<50%) diagnosed with CAG after PCI; and control group, consisting of 96 volunteers with no coronary artery disease. The levels of LOX-1 were measured in each patient by using an enzyme-linked immunosorbent assay, and their general information as well as laboratory parameters were recorded and followed up during a period of 2 years.LOX-1 levels gradually increased after PCI along with the progression of the lesion in the 3 groups. The levels of LOX-1 were significantly higher in the ISR group than in the other 2 groups (P < .001). LOX-1 levels were correlated with the levels of uric acid (UA) (r = 0.289, P = .007), creatinine (CREA) (r = .316, P = .003), and high-density lipoprotein cholesterol (HDL-C) (r = −0.271, P = .012), whereas no statistically significant correlation was detected with the Gensini score (r = 0.157, P = .141). The sensitivity and specificity of LOX-1 were 81.5% and 55.7%, respectively, with the most optimal threshold (5.04 μg/L). The area under curve (AUC) of the receiver operator characteristic (ROC) curve of LOX-1 was 0.720, and LOX-1 had the highest AUC compared with CREA, UA, and HDL-C, both individually and in combination.A high level of LOX-1 in the early period after PCI has a certain predictive power and diagnostic value for ISR. However, the level of LOX-1 is not related to the Gensini score of coronary artery after PCI, and CREA and UA, which are weakly related to LOX-1, have no obvious synergy in the diagnosis of ISR with LOX-1.
机译:支架内再狭窄(ISR)是与经皮冠状动脉介入治疗(PCI)相关的最常见并发症。尽管一些研究报告了凝集素样氧化低密度脂蛋白受体1(LOX-1)与ISR之间存在关联,但尚无足够的临床验证数据来支持这种联系。在此,我们报告了一项横断面研究,旨在探讨LOX-1作为进行PCI患者预后诊断的生物标志物的可行性。包括三组:ISR组,包括99例经冠状动脉造影(CAG)诊断的ISR患者PCI之后;病变组,包括87例PCI后被诊断为CAG的冠状动脉狭窄患者(<50%);对照组为96名无冠心病的志愿者。通过酶联免疫吸附测定法测量每位患者的LOX-1水平,并记录其一般信息以及实验室参数,并在2年内进行随访.PCI术后LOX-1水平逐渐升高随着3组病变的进展。 ISR组中LOX-1的水平明显高于其他2组(P <0.001)。 LOX-1水平与尿酸(UA)(r = 0.289,P = .007),肌酐(CREA)(r = .316,P = .003)和高密度脂蛋白胆固醇(HDL)的水平相关-C)(r = -0.271,P = .012),而与Gensini评分之间没有统计学上的显着相关性(r = 0.157,P = .141)。 LOX-1的敏感性和特异性分别为81.5%和55.7%,最佳阈值为5.04μg/ L。 LOX-1的接收机操作员特性(ROC)曲线的曲线下面积(AUC)为0.720,与CREA,UA和HDL-C相比,LOX-1的AUC最高,无论是单独还是组合使用。 PCI术后早期LOX-1的水平对ISR具有一定的预测能力和诊断价值。但是,LOX-1的水平与PCI后冠状动脉的Ge​​nsini评分无关,与LOX-1弱相关的CREA和UA在用LOX-1诊断ISR中没有明显的协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号